Discovered and developed by Pfizer, Zeldox is a serotonin and dopamine antagonist that is effective in treating the wide range of positive, negative and depressive symptoms associated with schizophrenia. Positive symptoms include visual and auditory hallucinations and delusions.
Schizophrenia is a chronic illness that requires lifelong treatment.
The 4,500 patient worldwide clinical trials program was the largest ever conducted for a novel antipsychotic medicine prior to launch. In addition to its demonstrated efficacy in treating schizophrenia, Zeldox was demonstrated to be weight neutral, a feature that distinguishes it from all marketed atypical antipsychotics. Significant weight gain, associated with many currently available antipsychotic medicines, is distressing and stigmatizing to patients and often results in non-compliance. Patients who gain weight may also be at greater risk for cardiovascular complications such as increased lipid levels and poor glycemic control. Clinical trial data also showed that Zeldox was associated with a low incidence of abnormal movements and sexual dysfunction.